Zacks: Analysts Expect Obseva SA (OBSV) Will Announce Earnings of -$0.35 Per Share
Wall Street analysts expect Obseva SA (NASDAQ:OBSV) to report earnings per share (EPS) of ($0.35) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Obseva SA’s earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.32). The firm is expected to report its next earnings results on Monday, January 1st.
On average, analysts expect that Obseva SA will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.62) to ($1.09). For the next fiscal year, analysts forecast that the company will post earnings of ($1.86) per share, with EPS estimates ranging from ($1.96) to ($1.75). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Obseva SA.
OBSV has been the subject of a number of research analyst reports. Leerink Swann initiated coverage on Obseva SA in a research report on Tuesday, February 21st. They issued an “outperform” rating and a $21.00 target price for the company. Credit Suisse Group AG reissued an “outperform” rating and issued a $27.00 target price on shares of Obseva SA in a research report on Tuesday. Finally, Jefferies Group LLC initiated coverage on Obseva SA in a research report on Tuesday, February 21st. They issued a “buy” rating and a $21.00 target price for the company.
Obseva SA (NASDAQ:OBSV) traded down 2.64% during trading on Tuesday, hitting $6.63. The stock had a trading volume of 68,274 shares. The company’s market cap is $26.98 million. The firm has a 50 day moving average of $10.61 and a 200-day moving average of $11.38. Obseva SA has a one year low of $6.22 and a one year high of $14.69.
About Obseva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva SA and related companies with MarketBeat.com's FREE daily email newsletter.